Compare · ABIO vs ORKA
ABIO vs ORKA
Side-by-side comparison of ARCA biopharma Inc. (ABIO) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABIO and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.04B, about 158.3x ABIO ($25.5M).
- ORKA has hit the wire 11 times in the past 4 weeks while ABIO has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for ABIO).
- Company
- ARCA biopharma Inc.
- Oruka Therapeutics Inc.
- Price
- $2.45-2.78%
- $66.95+4.56%
- Market cap
- $25.5M
- $4.04B
- 1M return
- -
- +3.69%
- 1Y return
- -
- +407.58%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
ARCA biopharma Inc.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Latest ABIO
- Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.
- Director Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)
- ARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SC 13D filed by ARCA biopharma Inc.
- New insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)
- New insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)
- SEC Form 3 filed by new insider Kulkarni Samarth
- SEC Form 3 filed by new insider Dambkowski Carl
- SEC Form 3 filed by new insider Ball Kristine M
- SEC Form 3 filed by new insider Quinlan Paul T
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)